".................. EF + PA elicits significant effects on different immune cells which is significantly associated with higher OS. Multivariate analysis identified potential target populations for phase III.
Am I the only dumb klutz that thinks this was worthy of a PR to the market?
Hi Ahjay,
Dumb - certainly not, klutz - cant ascertain !
Can only assume our revitalized director LC, left her glasses on the kitchen bench as she scurried off to the office ! Agree good news is hard enough to come by these days without letting any slip through the cracks.
Ann: Immutep to present Phase IIb breast cancer data at ESMO 2022, page-18
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 41.0¢ | 39.5¢ | $1.515M | 3.783M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 115519 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 37481 | 2 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |